Milestone achieved: FDA approves nivolumab in combination with cisplatin and gemcitabine for metastatic urothelial carcinoma

被引：0

作者：

Khaliq, Nawal ^{[1
]}

Sohail, Maryam ^{[2
]}

Younas, Shanzay ^{[3
]}

Ishaq, Maryam ^{[4
]}

Akilimali, Aymar ^{[5
]}

机构：

[1] Dow Univ Hlth Sci, Karachi, Pakistan

[2] DG Khan Med Coll, Dera Ghazi Khan, Pakistan

[3] Faisalabad Med Univ, Punjab Med Coll, Faisalabad, Pakistan

[4] Khyber Med Coll, Peshawar, Khyber Pakhtunk, Pakistan

[5] Med Res Circle MedReC, Dept Res, Goma, DEM REP CONGO

来源：

ANNALS OF MEDICINE AND SURGERY | 2024年 / 86卷 / 11期

关键词：

IMMUNOTHERAPY; CHEMOTHERAPY; CANCER;

D O I：

10.1097/MS9.0000000000002601

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6389 / 6392

页数：4

共 15 条

[1] Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma [J].

Bajorin, D. F. ;

Witjes, J. A. ;

Gschwend, J. E. ;

Schenker, M. ;

Valderrama, B. P. ;

Tomita, Y. ;

Bamias, A. ;

Lebret, T. ;

Shariat, S. F. ;

Park, S. H. ;

Ye, D. ;

Agerbaek, M. ;

Enting, D. ;

McDermott, R. ;

Gajate, P. ;

Peer, A. ;

Milowsky, M., I ;

Nosov, A. ;

Antonio Jr, J. N. ;

Tupikowski, K. ;

Toms, L. ;

Fischer, B. S. ;

Qureshi, A. ;

Collette, S. ;

Unsal-Kacmaz, K. ;

Broughton, E. ;

Zardavas, D. ;

Koon, H. B. ;

Galsky, M. D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (22) :2102-2114

[2] Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab [J].

Chiang, Ryan S. ;

Glover, Michael J. ;

Khaki, Ali Raza ;

Srinivas, Sandy .

ONCOTARGETS AND THERAPY, 2022, 15 :1259-1269

[3] Cisplatin in cancer therapy: Molecular mechanisms of action [J].

Dasari, Shaloam ;

Tchounwou, Paul Bernard .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 740 :364-378

[4] Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium:: Results of a randomized phase 2 trial [J].

Dogliotti, Luigi ;

Carteni, Giacomo ;

Siena, Salvatore ;

Bertetto, Oscar ;

Martoni, Andrea ;

Bono, Aldo ;

Amadori, Dino ;

Onat, Haluk ;

Marini, Luca .

EUROPEAN UROLOGY, 2007, 52 (01) :134-141

[5]

FDA, FDA Approves Nivolumab Plus Ipilimumab and Chemotherapy for FirstLine Treatment of Metastatic NSCLC,

[6] Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options [J].

Koufopoulou, Maria ;

Miranda, Paulo A. P. ;

Kazmierska, Paulina ;

Deshpande, Sohan ;

Gaitonde, Priyanka .

CANCER TREATMENT REVIEWS, 2020, 89

[7] Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials [J].

Mamede, Isadora ;

Escalante-Romero, Lorena ;

Celso, Davi S. Goncalves ;

Reis, Pedro C. Abrahao ;

Dacoregio, Maria Inez ;

Alves, Ana Caroline ;

Stecca, Carlos .

CLINICAL GENITOURINARY CANCER, 2024, 22 (05)

[8]

Medscape, Opdivo (nivolumab) dosing, indications, interactions, adverse effects, and more Internet

[9] A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium [J].

Miller, Kurt ;

Morant, Rudolf ;

Stenzl, Arnulf ;

Zuna, Ivan ;

Wirth, Manfred .

UROLOGIA INTERNATIONALIS, 2016, 96 (01) :5-13

[10]

Mount Sinai, Bladder Cancer Medication: Antineoplastics, Antimetabolite, Antineoplastics, Vinca Alkaloid, Antineoplastics, Anthracycline, Antineoplastics, Alkylating, Antineoplastics, Antimicrotubular, PD-1/PD-L1 Inhibitors, FGFR Inhibitors, Anti-Nectin-4 Monoclonal Antibodies, Gene Therapies, Oncologics

← 1 2 →